Micafungin Dose Adjustment
No dose adjustment of micafungin is required for renal impairment, hepatic impairment (including severe), or in elderly patients; pediatric dosing is weight-based and differs from adult fixed dosing. 1
Adults with Renal Impairment
Micafungin requires no dose adjustment regardless of severity of renal dysfunction. The FDA label clearly demonstrates that severe renal impairment (creatinine clearance <30 mL/min) does not significantly alter micafungin Cmax or AUC 1. Since micafungin is highly protein-bound (>99%), it is not dialyzable, and supplementary dosing after hemodialysis is not needed 1. This is consistent with the echinocandin class characteristic of minimal renal elimination 2.
- Standard adult dosing remains: 100 mg daily for candidemia/invasive candidiasis, 150 mg daily for esophageal candidiasis, 50 mg daily for prophylaxis
- No adjustment needed for any degree of renal impairment or dialysis
Adults with Hepatic Impairment
No dose adjustment is necessary even in severe hepatic impairment (Child-Pugh C). While moderate hepatic impairment reduces micafungin Cmax and AUC by approximately 22%, and severe hepatic impairment reduces them by approximately 30%, these reductions are not clinically meaningful 1. The resulting exposures remain comparable to those in patients with systemic Candida infections who respond to treatment 3.
- The M-5 metabolite increases 2.3-fold in severe hepatic impairment, but this does not warrant dose adjustment 1
- Unlike caspofungin (which requires dose reduction in moderate-severe hepatic dysfunction), micafungin maintains consistent dosing across all degrees of hepatic impairment 2
Important caveat: The lower albumin concentrations in hepatic impairment may result in higher unbound drug concentrations, but the magnitude is not clinically significant 3.
Elderly Patients
No specific dose adjustment is required based on age alone. The evidence does not identify age as an independent covariate requiring dose modification. Standard adult dosing applies to elderly patients, though clinicians should remain vigilant for age-related comorbidities (particularly renal or hepatic dysfunction) that might affect overall clinical status—though as noted above, even these do not require micafungin dose changes.
Pediatric Patients
Pediatric dosing is weight-based and body surface area-based, differing substantially from adult fixed dosing 4:
For Prophylaxis (nonapproved indication):
- Children ≥1 year: 50 mg/m² per day IV (loading dose 70 mg/m² on day 1), maximum 70 mg/day
- Infants 3-12 months: 50 mg/m² per day IV
- Infants <3 months: 25 mg/m² per day IV
For Treatment (nonapproved indication):
- 1 mg/kg per day IV (or 50 mg for children ≥50 kg) as one option
- 2-4 mg/kg per day IV (or 100-200 mg for children ≥50 kg) for more intensive treatment
Pharmacokinetic Considerations in Pediatrics:
The population pharmacokinetic data shows micafungin exposure is dose-proportional across pediatric age ranges 1. For children ≤30 kg receiving 1 mg/kg, steady-state AUC is approximately 55 mcg·h/mL with clearance of 0.328 mL/min/kg. For children >30 kg, clearance is lower at 0.241 mL/min/kg 1.
Critical point: Pediatric clearance is higher than adults (as expected), necessitating weight-based rather than fixed dosing to achieve comparable drug exposures 5, 6.
Key Clinical Pitfalls
- Do not reduce micafungin dose in hepatic impairment despite lower measured drug levels—the exposure remains therapeutically adequate
- Do not add supplemental doses after dialysis—the drug is not removed by hemodialysis
- Do not use adult fixed doses in children—this will result in subtherapeutic exposures due to higher pediatric clearance
- Consider therapeutic drug monitoring in critically ill patients with altered volume of distribution, severe hypoalbuminemia, or extracorporeal circuits, targeting Cmin >1 mg/L 7